Patents Examined by Bao Li
-
Patent number: 9833506Abstract: The present invention provides screening methods which may be regarded as in vitro or ex vivo methods of interrogating the immune system to understand what viral antigens are “seen” and responded to by T cells of the immune systems during viral infection. The screening methods further link in vitro or ex vivo responses to progression of infection in subjects.Type: GrantFiled: December 21, 2012Date of Patent: December 5, 2017Assignees: HVIVO SERVICES LIMITED, UNIVERSITY OF SOUTHAMPTONInventors: Robert Lambkin-Williams, John S. Oxford, Thomas Wilkinson
-
Patent number: 9821049Abstract: The present invention relates to vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to methods of conferring protective immunity to Norovirus infections in a human subject.Type: GrantFiled: March 15, 2013Date of Patent: November 21, 2017Assignee: Takeda Vaccines, Inc.Inventors: Charles Richardson, Thomas S. Vedvick, Thomas R. Foubert, Robert F. Bargatze, William Tino
-
Patent number: 9814907Abstract: The present invention relates to a recombinant self-assembled protein comprising a target-oriented peptide and a use thereof. The recombinant self-assembled protein according to the present invention, comprising a target-oriented peptide, does not require an additional process for providing target-orientedness, and is thus capable of delivering a desired drug to a target tissue or target cell without using additives, such as chemical binders or stabilizers; therefore, the protein can be used for photothermal therapy, drug delivery, imaging, or the like. In particular, according to the present invention, it is possible to prepare gold-protein nanoparticle fusions in which uniform high-density gold nanoparticles having target-orientedness are bound to protein surfaces, without an additional process of surface stabilization or process for providing target-orientedness.Type: GrantFiled: September 9, 2015Date of Patent: November 14, 2017Assignee: Korea University Research and Business FoundationInventors: Jeewon Lee, Koo-Chul Kwon
-
Patent number: 9809800Abstract: A method for stably and easily producing a parvovirus having a high infectivity titer is provided. The problem is solved by a method for producing a parvovirus having an infectivity titer as high as 108 TCID50/mL or more in a culture supernatant, comprising the steps of inoculating a seed virus of the parvovirus into a culture substrate comprising host cells having a cell density of 1/500 to 1/20 of the cell density of the host cells confluently grown and a medium at a multiplicity of infection of 0.0001 to 0.1, culturing for a period of 5 to 11 times the doubling time of the host cells, and recovering a culture supernatant.Type: GrantFiled: September 5, 2013Date of Patent: November 7, 2017Assignee: ASAHI KASEI MEDICAL CO., LTD.Inventor: Koichiro Yanagida
-
Patent number: 9791445Abstract: The present invention describes subunit vaccines containing Gn and Gc glycoproteins of the Rift Valley Fever Virus, including nucleic acids encoding such glycoproteins, host cells, vectors, and immunoreagents generated with the glycoproteins, methods of vaccination, methods of diagnosis, and kits.Type: GrantFiled: January 28, 2014Date of Patent: October 17, 2017Assignee: Kansas State University Research FoundationInventors: Juergen A. Richt, Bonto Faburay, William Wilson
-
Patent number: 9771428Abstract: Methods are provided for treating a subject with for an intracellular pathogen infection, by administering an agent that reduces the binding of CD47 on a infected cell to SIRP? on a host phagocytic cell, in an effective dose for increasing the phagocytosis of infected cells.Type: GrantFiled: February 5, 2014Date of Patent: September 26, 2017Assignees: The Board of Trustees of the Leland Stanford Junior University, The Regents of the University of California, The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Kipp Andrew Weiskopf, Kim J. Hasenkrug, Cheryl A. Stoddart, Joseph M. McCune, Irving L. Weissman
-
Patent number: 9766239Abstract: Synbodies specific for Norovirus and coupled with a substrate provide Norovirus binding and detection platforms (FIG. 1). A Norovirus capturing platform, comprising one or more synbodies selected from the group consisting of synbodies 6-6, 92-92, 93-93, and 94-94 coupled to a substrate, has been found to found to bind with either GII.4 Minerva or both GII.4 Minerva and GII.4 Sydney# strains of norovirus.Type: GrantFiled: March 12, 2014Date of Patent: September 19, 2017Assignee: Arizona Board of Regents on Behalf of Arizona State UniversityInventors: Nidhi Gupta, Chris Diehnelt, Charles Arntzen, Stephen Johnston
-
Patent number: 9766254Abstract: The invention relates to in vitro method for quantitating the antibodies specific for High mobility group box I (HMGB1) contained in a sample, in particular a serum sample or a cerebrospinal fluid sample obtained from a patient, and the use of this method in the prognostic and/or diagnosis of neurological disorders. These methods are in particular applicable to the monitoring of the human immunodeficiency virus (HIV) infection of a subject who is known to be infected with HIV and in the prognostic and/or diagnostic of the state of progression of Acquired immune deficiency syndrome (AIDS) or the state of progression toward AIDS, in particular the state of progression or the state of progression toward neurological disorders associated with AIDS. Finally, the invention is also about method to determine the immune deficiency or level of immune activation of a patient, in particular a HIV-infected patient.Type: GrantFiled: September 11, 2015Date of Patent: September 19, 2017Assignee: INSTITUT PASTEURInventors: Marie-Lise Gougeon, Beatrice Poirier-Beaudoin, Valerie Seffer, Hela Saidi
-
Patent number: 9764026Abstract: The present invention relates to compositions, methods, and kits for eliciting an immune response to at least one CMV antigen expressed by a cancer cell, in particular for treating and preventing cancer. CMV determination methods, compositions, and kits also are provided.Type: GrantFiled: April 8, 2015Date of Patent: September 19, 2017Assignee: Duke UniversityInventors: John H. Sampson, Duane A. Mitchell
-
Patent number: 9738690Abstract: The present invention relates to the field of vaccination or immunization, in particular therapeutic vaccination, and diagnosis. Pharmaceutical compositions and kits capable of eliciting a protective immune response against polyoma virus JC (JCV) are disclosed, which may be used e.g., for therapy or for prevention of progressive multifocal leukoencephalopathy (PML) and/or progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome (PML-IRIS). Individuals in danger of such PML or PML-IRIS may, e.g., be immuno-compromised or immunosuppressed patients or patients having an autoimmune disease eligible for immunosuppressive treatment. The invention also relates to compositions comprising at least one CD4+ epitope of a JCV protein and to therapeutic, prophylactic and diagnostic uses thereof.Type: GrantFiled: July 23, 2012Date of Patent: August 22, 2017Assignee: UNIVERSITAET ZUERICHInventors: Ilijas Jelcic, Roland Martin, Sven Schippling, Mireia Sospedra, Sara Yousef
-
Patent number: 9730997Abstract: Described herein are compositions and methods for stimulating an immune response to one or more proteins derived from one or more respiratory pathogens. In particular, the invention relates to alphavirus replicons, alphavirus vector constructs, alphavirus replicon particles expressing one or more antigens derived from one or more respiratory pathogens as well as to method of making and using these immunogenic compositions.Type: GrantFiled: August 20, 2014Date of Patent: August 15, 2017Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Silvia Perri, John Polo, Yasushi Uematsu, Catherine Greer
-
Patent number: 9719069Abstract: Disclosed are compositions and methods that relate generally to viruses, and more particularly to the agents and their identification and use of anti-HIV agents which cause latently infected cells to reactivate.Type: GrantFiled: January 27, 2010Date of Patent: August 1, 2017Assignee: UNIVERSITY OF UTAH RESEARCH FOUNDATIONInventors: Vicente Planelles, Alberto Bosque
-
Patent number: 9714272Abstract: The invention relates to polynucleotides coding for the PPVO viral genome, to fragments of the polynucleotides coding for the PPVO genome and to polynucleotides coding for individual open reading frames (ORFs) of the PPVO viral genome. The invention also relates to recombinant proteins expressed from the above mentioned polynucleotides and to fragments of said recombinant proteins, and to the use of said recombinant proteins or fragments for the preparation of pharmaceutical compositions.Type: GrantFiled: September 8, 2014Date of Patent: July 25, 2017Assignee: AICURIS GMBH & CO. KGInventors: Olaf Weber, Sonja Maria Tennagels, Angela Siegling, Tobias Schlapp, Andrew Allan Mercer, Stephen Bruce Fleming, Hans-Dieter Volk
-
Patent number: 9708392Abstract: The present invention relates to monoclonal antibodies that bind or neutralize Orthopoxviruses. The invention provides such antibodies, fragments of such antibodies retaining B5 or A33 binding ability, fully human antibodies retaining B5 or A33 binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.Type: GrantFiled: March 19, 2015Date of Patent: July 18, 2017Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Zhaochun Chen, Patricia Earl, Bernard Moss, Suzanne U. Emerson, Robert H. Purcell
-
Patent number: 9702005Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.Type: GrantFiled: November 26, 2013Date of Patent: July 11, 2017Assignee: ABL SAInventors: Angeline Ingrid Bartholomeusz, Stephen Alister Locarnini, Anna Ayres, Danielle Colledge, Joseph John Sasadeusz, Peter William Angus, William Sievert
-
Patent number: 9701982Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.Type: GrantFiled: February 5, 2013Date of Patent: July 11, 2017Assignee: ABL SAInventors: Angeline Ingrid Bartholomeusz, Stephen Locarnini, Anna Ayres, Margaret Littlejohn, Paul Desmond, Peter William Angus
-
Patent number: 9701945Abstract: The present invention relates to the development and manufacturing of viral vaccines. In particular, the invention relates to the field of industrial production of viral vectors and vaccines, more in particular to the use of avian embryonic stem cells, preferably the EBx® cell line derived from chicken embryonic stem cells, for the production of viral vectors and viruses. The invention is particularly useful for the industrial production of viral vaccines to prevent viral infection of humans and animals.Type: GrantFiled: May 21, 2015Date of Patent: July 11, 2017Assignee: ValnevaInventors: Majid Mehtali, Patrick Champion-Arnaud, Arnaud Leon
-
Patent number: 9701944Abstract: The invention relates to a cDNA molecule which encodes the nucleotide sequence of the full length antigenomic (+)RNA strand of a measles virus (MV) originating from an approved vaccine strain. It also concerns the preparation of immunogenic compositions using said cDNA.Type: GrantFiled: March 24, 2015Date of Patent: July 11, 2017Assignees: Institut Pasteur, Centre National de la Recherche ScientifiqueInventors: Frederic Tangy, Chantal Combredet, Valerie Labrousse-Najburg, Michel Brahic
-
Patent number: 9696307Abstract: Methods and compositions for determining whether a subject is at risk for PML, including subjects being treated with immunosuppressants, by determining whether the subject harbors a JCV variant with reduced binding for sialic acid relative to a normal JCV, are presented. Furthermore, combinations of JCV-VP1 sequence variations that are associated with PML and that can be used as a basis of an assay for identifying subjects susceptible to PML, subjects with PML (e.g., early stage PML), or subjects at risk of developing PML in response to an immunosuppressive treatment are provided.Type: GrantFiled: January 22, 2015Date of Patent: July 4, 2017Assignee: Biogen MA Inc.Inventors: Leonid Gorelik, Alexey Lugovskoy
-
Patent number: 9696308Abstract: A protein complex isolated from its natural medium and including the ZEBRA protein of sequence SEQ ID NO: 1, the isolated protein complex having the following properties: it is more stable than the ZEBRA protein, in particular it is more resistant to the action of the proteases than the ZEBRA protein, it is capable of specifically binding the AZ125 and AZ130 monoclonal antibodies, it is soluble in a body fluid, and in particular a body fluid selected from the group constituted by blood and serum, and to its detection process and the uses of this process for the prognosis or diagnosis of lymphoproliferative episodes associated with the EBV.Type: GrantFiled: December 4, 2012Date of Patent: July 4, 2017Assignee: UNIVERSITE JOSEPH FOURIERInventors: Emmanuel Drouet, Mohammed Habib, Felix Agbalika